Iteos Therapeutics Inc
NASDAQ:ITOS

Watchlist Manager
Iteos Therapeutics Inc Logo
Iteos Therapeutics Inc
NASDAQ:ITOS
Watchlist
Price: 7.2822 USD -2.25%
Market Cap: 266m USD
Have any thoughts about
Iteos Therapeutics Inc?
Write Note

Iteos Therapeutics Inc
Cash from Financing Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Iteos Therapeutics Inc
Cash from Financing Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Financing Activities CAGR 3Y CAGR 5Y CAGR 10Y
Iteos Therapeutics Inc
NASDAQ:ITOS
Cash from Financing Activities
$1.1m
CAGR 3-Years
-85%
CAGR 5-Years
-46%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Cash from Financing Activities
-$2.8B
CAGR 3-Years
45%
CAGR 5-Years
25%
CAGR 10-Years
1%
Gilead Sciences Inc
NASDAQ:GILD
Cash from Financing Activities
-$6.8B
CAGR 3-Years
0%
CAGR 5-Years
4%
CAGR 10-Years
-3%
Amgen Inc
NASDAQ:AMGN
Cash from Financing Activities
-$5.3B
CAGR 3-Years
0%
CAGR 5-Years
21%
CAGR 10-Years
N/A
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Cash from Financing Activities
-$1.2B
CAGR 3-Years
1%
CAGR 5-Years
-55%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Cash from Financing Activities
-$1.5B
CAGR 3-Years
-55%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Iteos Therapeutics Inc
Glance View

Market Cap
266m USD
Industry
Biotechnology

iTeos Therapeutics, Inc. engages in the development of biopharmaceuticals therapeutic products and services. The company is headquartered in Watertown, Massachusetts and currently employs 94 full-time employees. The company went IPO on 2020-07-24. The firm is focused on the discovery and development of differentiated immuno-oncology therapeutics for patients. The firm's pipeline includes two clinical-stage programs: EOS-448 and Inupadenant (EOS-850). The Company’s lead antibody product candidate, EOS-448, is an antagonist of T-cell immunoreceptor with Ig and ITIM domains (TIGIT), an immune checkpoint with multiple mechanisms of action, which leads to immunosuppression. Its EOS-850, is designed as a selective small molecule antagonist of the adenosine A2a receptor (A2AR) in the adenosine triphosphate (ATP) adenosine pathway. The firm is conducting an open-label multi-arm Phase I/II clinical trial of inupadenant in adult cancer patients with advanced solid tumors.

ITOS Intrinsic Value
2.127 USD
Overvaluation 71%
Intrinsic Value
Price

See Also

What is Iteos Therapeutics Inc's Cash from Financing Activities?
Cash from Financing Activities
1.1m USD

Based on the financial report for Dec 31, 2023, Iteos Therapeutics Inc's Cash from Financing Activities amounts to 1.1m USD.

What is Iteos Therapeutics Inc's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 5Y
-46%

Over the last year, the Cash from Financing Activities growth was -44%. The average annual Cash from Financing Activities growth rates for Iteos Therapeutics Inc have been -85% over the past three years , -46% over the past five years .

Back to Top